Roche's Genentech Receives FDA Priority Review For Enspryng As First At-Home Subcutaneous Treatment For Thyroid Eye Disease

ROCHE HOLDINGS AG
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG

ROCHE HOLDINGS AG

RHHBF

0.00

ROCHE HOLDINGS AG

RHHBY

0.00

ROCHE HOLDINGS AG

RHHVF

0.00
  • The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED
  • Enspryng (satralizumab) has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED
  • TED is an autoimmune disease affecting approximately 155 out of every 100,000 people that can lead to facial disfigurement and vision-threatening complications if left untreated
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.